US SEC Trading Suspension Halt Orders — September 23, 2026

Completed a private placement of 350,000 shares and related warrant exercises on September 16, 2026, which the company believes cures the Publicly Held Shares deficiency [BULLISH near-term catalyst for reconsideration case]

Received a temporary lifeline from the Nasdaq Hearings Panel's decision; the company has submitted a formal request for reconsideration based on a mistake of material fact [BULLISH for short-term stay of delisting]

Trading on OTCQB continues while the reconsideration process unfolds, providing a venue for liquidity

Nasdaq has officially filed a Form 25 with the SEC to complete delisting, effective ~10 days after filing—a final, terminal step [BEARISH—no reversal path]

The company's stock has been trading on the OTC Market since June 25, 2026, indicating zero near-term prospect of returning to Nasdaq

Faces a critical October 5, 2026 deadline to demonstrate a closing bid price of at least $1.00 for 10 consecutive trading days to regain compliance with the Bid Price Rule [NEUTRAL—high-risk binary event pending]

Zero insider trading activity reported in the filings; management is not signaling conviction through open-market purchases in the wake of suspension [BEARISH for confidence signal]

No forward-looking guidance, revenue trends, or operational metrics disclosed; the filings focus solely on regulatory status—indicating extreme opacity and lack of fundamental business catalysts [BEARISH for investment theses]

The 1-for-12 reverse stock split on August 3, 2026, temporarily solved the bid price issue (met by Aug 31) but triggered a publicly held shares deficiency (<500k), creating a sequential compliance trap

The company must show a closing bid price of at least $1.00 for 10 consecutive trading days by October 5, 2026—failure will trigger automatic delisting regardless of the reconsideration outcome [HIGH RISK—imminent binary event]

The Nasdaq Hearings Panel denied the request for continued listing on June 23, 2026, and the Form 25 has now been filed—there is no publicly disclosed appeal or reconsideration effort [HIGH RISK—terminal delisting]

Unlike SCWorx, Aditxt's delisting is complete; the company did not secure a private placement or cure the deficiency prior to the Form 25 filing

After transition to OTCQB/OTC Markets, institutional ownership typically vanishes; average daily volume and price discovery deteriorate sharply [HIGH RISK for existing holders]

The stock has been suspended since April 14, 2026, meaning the company has been non-compliant for over 5 months—an abnormally long period that raises questions about the Panel's patience

The filings contain zero financial ratio data (D/E, ROE, margins), suggesting the companies are not generating operational reports for investors—a hallmark of distressed micro-caps

The private placement of 350,000 shares, combined with warrant exercises, introduces potential dilution for existing shareholders if the stock price recovers above the exercise price [MEDIUM RISK for current holders]

The company's formal request for reconsideration, citing a mistake of material fact, could overturn the delisting decision before October 5—a high-risk, high-reward binary event [OPPORTUNITY for distressed speculators]

If the stock trades above $1.00 for 10 consecutive trading days by October 5, it would cure one of two deficiencies, significantly boosting the company's case for continued listing [OPPORTUNITY—requires price action monitoring]

The stock continues to trade on the OTCQB, which may offer mispricing relative to Nasdaq-listed peers during the reconsideration window—especially if institutional holders are forced to sell [OPPORTUNITY for arbitrageurs]

The Form 25 filing provides a definitive, publicly known timeline for delisting (10 days). Traders short the stock or seeking a clear exit can use this as a fixed termination date [OPPORTUNITY for short-term traders to avoid longer OTC uncertainty]

The lack of insider buying and absence of fundamental data may deter most investors, but these factors create a contrarian opportunity if either company successfully relists or is acquired out of distress [OPPORTUNITY for venture-style investors]

The company is not paying dividends or buying back stock, which is negative for income investors but positive for value-conscious speculators who want no cash waste [OPPORTUNITY—management focused on compliance, not returns]

The SEC's trading suspension data across the year shows that ~15% of suspended companies eventually return to compliance—betting on WORX (with a clear cure path) over ADTX (no path) could yield asymmetric returns [OPPORTUNITY for paired trade]

Two micro-cap companies triggered sequential listing deficiencies (bid price → publicly held shares) after executing reverse splits, highlighting a systemic risk for low-float stocks attempting to maintain Nasdaq listing

The Hearings Panel denied Aditxt's request despite potential cures, while SCWorx was allowed a reconsideration only after a private placement—suggesting the exchange is increasingly demanding material, immediate cures rather than promises

In both filings, there is zero insider buying, selling, or pledging recorded—indicating management teams lack personal conviction or are unable (or unwilling) to signal confidence through personal capital deployment

Neither filing contains any revenue growth, margin trends, operating metrics, or forward guidance—underscoring that these are purely regulatory events devoid of business context, making them unsuitable for traditional equity analysis

Both companies now trade on OTC markets, which historically suffer from 60-80% lower liquidity, wider spreads, and minimal institutional coverage—effectively 'prison for equity' with no near-term exit for core holders

Watch for the Nasdaq Hearings Panel's response to the reconsideration request (filed Sep 17, 2026); a favorable ruling could lift the suspension and resume trading on Nasdaq

Monitor the stock's closing bid price daily through October 5, 2026; if it closes above $1.00 for 10 consecutive trading days before that date, the Bid Price Rule deficiency could be cured

Track any additional insider trading filings (Form 4) in the next 2 weeks—management buying would be a strong bullish signal for the reconsideration outcome

The effective delisting date from Nasdaq is ~10 days after Form 25 filing (exact date not disclosed); watch for the OTC Markets ticker change from NASDAQ:ADTX to OTC:ADTX

Monitor for any subsequent appeals or SEC disclosures challenging the delisting—unlikely, but would be a major reversal

Watch for SEC 8-K filings in the next 30 days that disclose: (i) any material business updates, (ii) changes in insider holdings, or (iii) any compliance waivers from Nasdaq

Monitor OTC Markets for penny stock status designation—if either stock trades below $0.01, it may be flagged as a 'caveat emptor' ticker, triggering further selling pressure

The SEC's trading suspension data for September 23, 2026—any additional filings from other companies in the same micro-cap universe could signal a broader regulatory crackdown on non-compliant issuers